Last reviewed · How we verify
AFN50 injection
At a glance
| Generic name | AFN50 injection |
|---|---|
| Sponsor | AlphaNa Bioscience Company Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases (EARLY_PHASE1)
- Clinical Study of AFN50 Injection in the Autoimmune Diseases (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AFN50 injection CI brief — competitive landscape report
- AFN50 injection updates RSS · CI watch RSS
- AlphaNa Bioscience Company Limited portfolio CI